This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bavry, A. A. Articles by Bhatt, D. L. Search for Related Content PubMed PubMed Citation Articles by Bavry, A. A. Articles by Bhatt, D. L. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID TAXOL Medline Plus Health Information Blood Thinners Related Collections Cardiovascular Pharmacology Restenosis Platelet function inhibitors Catheter-based coronary interventions: stents Acute coronary syndromes Acute myocardial infarction Chronic ischemic heart disease

(Circulation. 2007;116:696-699.)
© 2007 American Heart Association, Inc.

Editorial

Drug-Eluting Stents

Dual Antiplatelet Therapy for Every Survivor?

Anthony A. Bavry, MD, MPH; Deepak L. Bhatt, MD

From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.

Correspondence to Dr Deepak L. Bhatt, Associate Director, Cleveland Clinic Cardiovascular Coordinating Center, Cardiac, Peripheral, and Carotid Intervention, Cleveland Clinic, 9500 Euclid Ave, Desk F25, Cleveland, OH 44195. E-mail bhattd@ccf.org

Key Words: Editorials • angioplasty • platelets • restenosis • stents • thrombosis • aspirin

An extract of the first 250 words of the full text is provided, because this article has no abstract.

No recent pharmaceutical or medical device has generated as much ongoing and expanding attention as drug-eluting stents (DES). In fact there has been an explosion of published reports on the topic within cardiology, medical, surgical and subspecialty journals. The device industry has repeatedly sent their own summaries of information directly to physicians, while mainstream media has kept the consumer and Wall Street appraised of safety concerns, often with sensational headlines. The Food and Drug Administration has also taken notice by convening a meeting on DES in late 2006. What have we learned through all this dissemination of data?

Article p 745

The introduction of DES was greeted with intense enthusiasm in a "perfect storm" sort of way. Device representatives were eager to promote this new product that could dramatically reduce restenosis.¹ Patients expected to be treated with this new and "better" technology. Lastly, cardiologists had a potent new tool at their disposal that they increasingly incorporated into practice until it became the default revascularization device instead of bare-metal stents in many parts of the world. This quick and widespread adoption in DES resulted in its frequent use in relatively untested and off-label indications. At the Cleveland Clinic, the use of DES mirrored the community and many interventional practices throughout the world, where the penetration of this device peaked at >90%.

While DES use was increasing, McFadden and colleagues sounded an alarm with the publication of a report on 4 patients who experienced late stent thrombosis.² Although this could have been . . . [Full Text of this Article]

This article has been cited by other articles:

				A. K. Chhatriwalla and D. L. Bhatt Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Be Continued for More Than One Year and Preferably Indefinitely Circ Cardiovasc Interv, December 1, 2008; 1(3): 217 - 225. [Full Text] [PDF]

				D. L. Bhatt, J. Scheiman, N. S. Abraham, E. M. Antman, F. K.L. Chan, C. D. Furberg, D. A. Johnson, K. W. Mahaffey, E. M. Quigley, R. A. Harrington, et al. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents J. Am. Coll. Cardiol., October 28, 2008; 52(18): 1502 - 1517. [Full Text] [PDF]

				Writing Committee Members, D. L. Bhatt, J. Scheiman, N. S. Abraham, E. M. Antman, F. K.L. Chan, C. D. Furberg, D. A. Johnson, K. W. Mahaffey, and E. M. Quigley ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents Circulation, October 28, 2008; 118(18): 1894 - 1909. [Full Text] [PDF]

				R. C. Becker, T. W. Meade, P. B. Berger, M. Ezekowitz, C. M. O'Connor, D. A. Vorchheimer, G. H. Guyatt, D. B. Mark, and R. A. Harrington The Primary and Secondary Prevention of Coronary Artery Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 776S - 814S. [Abstract] [Full Text] [PDF]

				D. L. Bhatt Intensifying Platelet Inhibition -- Navigating between Scylla and Charybdis N. Engl. J. Med., November 15, 2007; 357(20): 2078 - 2081. [Full Text] [PDF]